Symbols / MGRM $6.00 +0.00% Monogram Technologies Inc.

Healthcare • Medical Devices • United States • NCM
MGRM Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO —
Exch · Country NCM · United States
Market Cap 244.21M
Enterprise Value 231.23M
Income -18.30M
Sales —
FCF (ttm) -3.88M
Book/sh 0.24
Cash/sh 0.32
Employees 27
Insider 10d —
IPO May 18, 2023
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -12.50
PEG —
P/S —
P/B 25.10
P/C —
EV/EBITDA -16.52
EV/Sales —
Quick Ratio 2.08
Current Ratio 2.16
Debt/Eq 3.44
LT Debt/Eq —
EPS (ttm) -0.54
EPS next Y -0.48
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-08-15
Earnings (prior) 2025-08-15
ROA -72.90%
ROE -228.82%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 40.63M
Shs Float 30.58M
Insider Own 54.55%
Instit Own 4.97%
Short Float 0.49%
Short Ratio 1.66
Short Interest 161.43K
52W High 6.42
vs 52W High -6.61%
52W Low 1.92
vs 52W Low 212.76%
Beta 0.69
Impl. Vol. —
Rel Volume 9.73
Avg Volume 160.94K
Volume 1.57M
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $6.00
Price $6.00
Change 0.00%
About

As of October 7, 2025, Monogram Technologies Inc. was acquired by Zimmer Biomet Holdings, Inc.. Monogram Technologies Inc. engages in developing surgical robot to enable placement of patient optimized orthopedic implants in the United States. It intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. The company was formerly known as Monogram Orthopaedics, Inc. and changed its name to Monogram Technologies Inc. in May 2024. Monogram Technologies Inc. was founded in 2015 and is headquartered in Austin, Texas.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$6.00
Latest analyst target
3. DCF / Fair value
$-1.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-03-18 main Roth MKM Buy → Buy $5
2024-12-09 init Roth MKM — → Buy $4
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-11-25 KNAPE NOEL Chief Financial Officer — 288,461 $2.08 $599,999
Financials

No financial statements available. Data is sourced from Yahoo Finance and cached; historical storage may be added later.

SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category